Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Encephalomyelitis - Overview
Encephalomyelitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Encephalomyelitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Encephalomyelitis - Companies Involved in Therapeutics Development
AIM ImmunoTech Inc
Biovista Inc
Cortene Inc
F. Hoffmann-La Roche Ltd
K-Pax Pharmaceuticals Inc
Orion BioScience Inc
Trethera Corp
Virios Therapeutics, Inc
Encephalomyelitis - Drug Profiles
(celecoxib + famciclovir) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-38 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Target IL-10, NT-3 and LINGO-1 for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JM-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KPAX-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MCC-950 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ORNx-KI - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rintatolimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Chronic Fatigue Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Encephalomyelitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate NFE2L2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WEHI-345 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Encephalomyelitis - Dormant Projects
Encephalomyelitis - Product Development Milestones
Featured News & Press Releases
Apr 24, 2018: New Hope for Patients with Mylagic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Encephalomyelitis, 2021
Number of Products under Development by Companies, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development for Encephalomyelitis, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Encephalomyelitis - Pipeline by AIM ImmunoTech Inc, 2021
Encephalomyelitis - Pipeline by Biovista Inc, 2021
Encephalomyelitis - Pipeline by Cortene Inc, 2021
Encephalomyelitis - Pipeline by F. Hoffmann-La Roche Ltd, 2021
Encephalomyelitis - Pipeline by K-Pax Pharmaceuticals Inc, 2021
Encephalomyelitis - Pipeline by Orion BioScience Inc, 2021
Encephalomyelitis - Pipeline by Trethera Corp, 2021
Encephalomyelitis - Pipeline by Virios Therapeutics, Inc, 2021
Encephalomyelitis - Dormant Projects, 2021
Encephalomyelitis - Dormant Projects, 2021 (Contd..1)